TO THE EDITOR:

Acquired mutations leading to aberrant activation of JAK/STAT signaling are common in myeloproliferative neoplasms (MPNs). Ruxolitinib is a JAK1/2 tyrosine kinase inhibitor used to treat patients with certain MPNs.2-6  The US Food and Drug Administration originally approved ruxolitinib for the treatment of advanced myelofibrosis (MF) because of its efficacy reducing symptoms and splenomegaly in this morbid disease.4-6  Weight gain among cachectic patients treated with ruxolitinib was quickly identified and reported among measures of improved quality of life.4-8  Although the original rationale was to disrupt pathogenic signaling via the mutated JAK2(V617F), ruxolitinib proved efficacious in patients with or without this mutation. Ruxolitinib use has since become more widespread. Now with US Food and Drug Administration approval for polycythemia vera and graft-versus-host disease9,10  and with an ever-expanding pool of indications being sought,11,12...

You do not currently have access to this content.